Effects of antibiotics on the viability of and toxin production by Clostridium botulinum.
Clostridium botulinum
antibiotics
botulinum neurotoxin
botulism
toxin production
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
02
07
2021
received:
25
03
2021
accepted:
02
07
2021
pubmed:
6
7
2021
medline:
21
10
2021
entrez:
5
7
2021
Statut:
ppublish
Résumé
Clostridium botulinum causes infant and adult intestinal botulism by colonizing in the intestine and producing botulinum neurotoxin (BoNT). Antimicrobial agents are not currently used for treatment due to the potential facilitation of BoNT production and bacterial cell lysis, which releases toxins into the intestinal lumen. In this study, we analyzed effects of four antibiotics on the viability of and BoNT production by four C. botulinum group I strains. Our results indicate that metronidazole rapidly reduced their viability without enhancing BoNT production. Antibiotics with these properties may promote elimination of C. botulinum from the intestines while maintaining low levels of BoNT.
Identifiants
pubmed: 34219270
doi: 10.1111/1348-0421.12928
doi:
Substances chimiques
Anti-Bacterial Agents
0
Botulinum Toxins
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-437Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20wm0325025h0001
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI Grant Number 18H02654
Organisme : Japan Society for the Promotion of Science
ID : 18K07107
Informations de copyright
© 2021 The Societies and John Wiley & Sons Australia, Ltd.
Références
Arnon SS, Midura TF, Clay SA, Wood RM, Chin J. Infant botulism: epidemiological, clinical, and laboratory aspects. JAMA. 1977;237:1946-51.
Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Medicine. 1980;69:567-70.
Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. New Engl J Medicine. 2006;354:462-71.
Brook I. Infant botulism. J Perinatol. 2007;27:175-80.
Derman T, Korkeala H, Salo E, Lönnqvist T, Saxen H, Lindström M. Infant botulism with prolonged faecal excretion of botulinum neurotoxin and Clostridium botulinum for 7 months. Epidemiol Infect. 2014;142:335-9.
Glauser TA, Maquire HC, Sladky JT. Relapse of infant botulism. Ann Neurol. 1990;28:187-9.
Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis. 2000;6:458-65.
Solomon HM, Lynt RK Jr., Kautter DA, Lilly T Jr. Serological studies of Clostridium botulinum type E and related organisms. II. Serology of spores. J Bacteriol. 1969;98:407-14.
Hyytiä E, Björkroth J, Hielm S, Korkeala H. Characterisation of Clostridium botulinum groups I and II by randomly amplified polymorphic DNA analysis and repetitive element sequence-based PCR. Int J Food Microbiol. 1999;48:179-89.
Smith TJ, Hill KK, Foley BT, et al. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3,/Ba4 and/B1 clusters are located within plasmids. PLoS One. 2007;2:e1271.
Tabita K, Sakaguchi S, Kozaki S, Sakaguchi G. Distinction between Clostridium botulinum type A strains associated with food-borne botulism and those with infant botulism in Japan in intraintestinal toxin production in infant mice and some other properties. FEMS Microbiol Lett. 1991;79:251-56.
Umeda K, Seto Y, Kohda T, Mukamoto M, Kozaki S. Genetic characterization of Clostridium botulinum associated with Type B infant botulism in Japan. J Clin Microbio. 2009;47:2720-28.
Omura S, Imamura N, Oiwa R, et al. Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties. J Antibiotics. 1986;39:1407-12.
Gnocchi M, Gagliardi M, Gismondi P, Gaiani F, Angelis GLde', Esposito S. Updated Management Guidelines for Clostridioides difficile in Paediatrics. Pathogens. 2020;9:291.
Yanagihara K, Akamatsu N, Matsuda J, Kaku N, Katsumata K, Kosai K. Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118. J Infect Chemother. 2018;24:492-5.
Barash JR, Castles JB, Arnon SS. Antimicrobial susceptibility of 260 Clostridium botulinum types A, B, Ba and Bf strains and a neurotoxigenic Clostridium baratii type F strain isolated from California infant botulism patients. Antimicrob Agents Ch. 2018;62:e01594-18.
Goldstein EJC, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Ch. 2011;55:5194-9.
Sakaguchi G. Clostridium botulinum toxins. Pharmacol Therapeut. 1982;19:165-94.
Sugiyama H, Mills DC. Intraintestinal toxin in infant mice challenged intragastrically with Clostridium botulinum spores. Infect Immun. 1978;21:59-63.
Burr D, Sugiyama H. Susceptibility to enteric botulinum colonization of antibiotic-treated adult mice. Infect Immun. 1982;36:103-6.
Wang Y, Sugiyama H. Botulism in metronidazole-treated conventional adult mice challenged orogastrically with spores of Clostridium botulinum type A or B. Infect Immun. 1984;46:715-9.
Eagle H. The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J Exp Medicine. 1949;90:595-607.
Hancock R, Fitz-James PC. Some differences in the action of penicillin, bacitracin, and vancomycin on Bacillus megaterium. J Bacteriol. 1964;87:1044-50.
Watanakunakorn C. The antibacterial action of vancomycin. Rev Infect Dis. 1981;3(suppl:):S210-15.
Jordan DC, Inniss WE. Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature. 1959;184:1894-5.
Davies J, Spiegelman GB, Yim G. The world of subinhibitory antibiotic concentrations. Curr Opin Microbiol. 2006;9:445-53.
Dezfulian M, Dowell VR Jr. Cultural and physiological characteristics and antimicrobial susceptibility of Clostridium botulinum isolates from foodborne and infant botulism cases. J Clin Microbiol. 1980;11:604-9.
Swenson JM, Thornsberry C, McCroskey LM, Hatheway CL, Dowell VR Jr. Susceptibility of Clostridium botulinum to thirteen antimicrobial agents. Antimicrob Agents Chemother. 1980;18:13-9.
Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27:1169-72.